Hospital
Centerpoint Medical Center of Independence, LLC
Centerpoint Medical Center of Independence, LLC was paid $38.66M by Medicaid between Jan 2018 and Dec 2024, across 60 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoCENTERPOINT MEDICAL CENTER OF INDEPENDENCE, LLC
INDEPENDENCE, MO 64057
INDEPENDENCE, MO 64057
33aNPI1942247044assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.66M
24GClaims344,232
24DCodes billed60
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#7 of 74
Median peer was paid$4.44M
This provider vs. median8.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,485 | $11.25M | |
| 2019 | 34,860 | $9.21M | |
| 2020 | 28,886 | $4.53M | |
| 2021 | 49,701 | $1.84M | |
| 2022 | 69,271 | $3.80M | |
| 2023 | 71,194 | $4.47M | |
| 2024incomplete | 54,835 | $3.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 35,486 | 32,895 | $8.22M |
| X4011 | State-specific procedure code | 14% | 16,073 | 14,564 | $5.46M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 34,635 | 32,589 | $5.14M |
| 85027 | 9.9% | 50,466 | 44,773 | $3.84M | |
| 80053 | Comprehensive metabolic panel | 9.4% | 45,450 | 40,638 | $3.65M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.0% | 16,773 | 15,420 | $2.33M |
| 81025 | 3.8% | 11,487 | 10,554 | $1.45M | |
| 81001 | 3.7% | 16,653 | 15,227 | $1.45M | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.6% | 17,575 | 15,689 | $1.39M |
| 83690 | 3.1% | 12,912 | 11,781 | $1.20M | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 3,146 | 2,705 | $1.07M |
| 83735 | 1.1% | 17,252 | 15,756 | $438K |
48 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 3,633 | $425K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,312 | $243K |
| 84484 | <1% | 9,500 | $242K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,150 | $183K |
| 81003 | <1% | 3,960 | $175K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,427 | $166K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,124 | $159K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,768 | $159K |
| G0378 | Hospital observation service, per hour | <1% | 361 | $155K |
| 80306 | <1% | 3,935 | $154K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 657 | $132K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,464 | $119K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,570 | $107K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,178 | $78K |
| 85610 | <1% | 1,061 | $76K | |
| Y7506 | <1% | 84 | $68K | |
| 87430 | <1% | 997 | $50K | |
| 82550 | <1% | 663 | $42K | |
| 85730 | <1% | 492 | $41K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 762 | $37K |
| 83880 | <1% | 1,488 | $35K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,000 | $31K |
| 87081 | <1% | 540 | $27K | |
| 82553 | <1% | 173 | $25K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 118 | $21K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 72 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,825 | $10K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 80 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 39 | $8K |
| J3490 | Unclassified drugs | <1% | 2,943 | $5K |
| 87428 | <1% | 381 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 66 | $4K |
| 83605 | <1% | 462 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 333 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 309 | $2K |
| 29580 | <1% | 26 | $2K | |
| X4003 | <1% | 15 | $2K | |
| 76801 | <1% | 13 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 34 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 34 | $1K |
| 87807 | <1% | 95 | $859.50 | |
| 73610 | <1% | 13 | $491.63 | |
| 87040 | <1% | 71 | $441.32 | |
| 84702 | <1% | 18 | $294.77 | |
| 87210 | <1% | 41 | $139.63 | |
| 82728 | <1% | 12 | $83.43 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 13 | $79.43 |
| 87070 | <1% | 12 | $29.10 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRIGGINS, ZACHARY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Citrus Memorial Hospital, INC. | Inverness, FL | $7.71M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.